Ophthalmic Business News

The FDA approved Tyrvaya nasal spray for the treatment of signs and symptoms of dry eye disease, according to a press release from Oyster Point Pharma.

NEW YORK — The future of cataract surgery in the U.S. may involve divergent pathways in order to accommodate increasingly common “add-ons” without devaluing the procedure as a whole, according to one speaker here.

NEW YORK — In this Healio Video Perspective from OSN New York, Calvin W. Roberts, MD, discusses the role Lighthouse Guild is playing in creating a community that develops tools for the blind and visually impaired community.

Doctor: “We need to start doing InflammaDry on our dry eye disease patients again. I haven’t seen an ID in weeks. When did we quit using it?”

Applications for Beovu to treat diabetic macular edema have been accepted in the United States, Europe and Japan, according to a press release from Novartis.

The Eidon ultra-widefield lens module received 510(k) clearance from the FDA, according to a press release from iCare USA.

BVI is investing in and collaborating with Beyeonics Vision, providing a pathway to commercialization for Beyeonics One in the United States, according to a press release from BVI.

Ludwin Monz, PhD, who serves as the head of the Zeiss Medical Technology segment, is stepping down as president and CEO of the executive board of Carl Zeiss Meditec AG effective Dec. 31, according to a press release.

The Retinal Degeneration Fund announced the launch of Opus Genetics, which will aim to develop gene therapy treatments for orphan inherited retinal diseases, according to a press release.

Benjamin F. McGraw III, PharmD, has been appointed as the interim executive chairman of the board of directors at Aerie Pharmaceuticals, replacing Vicente Anido Jr., PhD, the former chairman and CEO, according to a press release.